ClinicalTrials.gg
CompletedNCT01235507Updated Nov 7, 2014Results posted

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)

A Phase 3 interventional study of methotrexate and tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Bosnia and Herzegovina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-07.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
82nd of 113
71 · median 130
Started
2011
with 6 others
Phase 3
47 of 113
1 open now
Registered
53rd of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 82nd largest by enrollment, is one of 7 that started in 2011, is one of 47 in phase 3, and was the 53rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate response to dis ease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Act emra at a dose of 8 mg/kg (maximum 800 mg) intravenously every 4 weeks for a tot al of 6 infusions. Methotrexate will be continued at a stable dose. Anticipated time on study treatment is 24 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Active moderate to severe rheumatoid arthritis (RA)
  • On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable dose of at least 15 mg/week for at least 6 weeks
  • Oral must have been at stable dose of \</= 10 mg/day prednisone (or equivalent) for at least 25 out of 28 days prior to first dose of study drug
  • Body weight \</= 150 kg

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of study entry
  • Rheumatic disease other than RA
  • Functional class IV according to American College of Rheumatology (ACR) classification
  • Prior history of or current inflammatory joint disease other then RA
  • Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline
  • Treatment with any biologic drug that is used in the treatment or RA
  • Intraarticular or parenteral within 6 weeks prior to baseline
  • Known active current or history of recurrent infection
  • History of or currently active primary or secondary immunodeficiency
  • Positive for
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • stable dose as prescribed

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)

    AEs, SAEs and AESI were recorded from the Screening Visit until the final visit at Week 24.

    Time frame: Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24

Secondary outcomes

  1. Mean Disease Activity Score Based on 28 Joint Count (DAS28) by Visit

    DAS28 was calculated using the 28 joints count, the C-reactive protein levels (CRP) and participant's global assessment (PtGA) of disease activity. The following formula was used to determine DAS28. DAS28 (equals) = 0.56 × (square root of) √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100- millimeter \[mm\] visual analog scale \[ VAS\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

    Time frame: Baseline, Weeks 8, 16 and 24

  2. Percentage of Participants Achieving Low Disease Activity (LDA) and Clinical Remission (CR) as Assessed Using DAS28

    DAS28 was calculated using the 28 joints count, the CRP and PtGA of disease activity. The following formula was used to determine DAS28. DAS28 = 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100-mm VAS). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Participants were considered to have low disease activity when DAS28 was less than or equal to (≤) 3.2 and in clinical remission when DAS28 scores were less than (\<) 2.6

    Time frame: Weeks 8, 16 and 24

  3. Swollen and Tender Joint Counts

    66 and 68 joints were assessed by the physician for tenderness or swelling respectively. The joints were counted as tender/not tender (tender=1; not tender=0) and swollen/not swollen (swollen=1; not swollen=0) and scored. The scores ranged from 0 to 66 for TJC and 0 to 68 for SJC. A negative change from baseline represents an improvement.

    Time frame: Baseline, Weeks 8, 16 and 24

  4. Physician's Global Assessment of Disease Activity

    Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.

    Time frame: Baseline, Weeks 8, 16 and 24

  5. Participant's Global Assessment of Disease Activity

    Participant's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.

    Time frame: Baseline, Weeks 8, 16 and 24

  6. Participant's Global Assessment of Pain

    Participant's global assessment of pain was performed using a 100 mm VAS ranging from no pain (0) at the left edge to unbearable pain (100) at the right edge. The distance in mm from the left edge of the scale was measured. A negative change from baseline represents an improvement.

    Time frame: Baseline, Weeks 8, 16 and 24

  7. CRP Levels

    CRP is a marker of acute phase inflammation and is measured in mg/L. A negative change from baseline represents an improvement.

    Time frame: Baseline, Weeks 8, 16 and 24

  8. Erythrocyte Sedimentation Rate (ESR)

    ESR is a marker of inflammation and is measured in millimeters per hour (mm/hour). A negative change from baseline represents an improvement.

    Time frame: Baseline, Weeks 8, 16 and 24

07

Results

Posted Oct 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab Plus Methotrexate (MTX)
Started71
Completed69
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

SecondaryMean Disease Activity Score Based on 28 Joint Count (DAS28) by Visit

DAS28 was calculated using the 28 joints count, the C-reactive protein levels (CRP) and participant's global assessment (PtGA) of disease activity. The following formula was used to determine DAS28. DAS28 (equals) = 0.56 × (square root of) √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100- millimeter \[mm\] visual analog scale \[ VAS\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Mean · units on a scale
Mean Disease Activity Score Based on 28 Joint Count (DAS28) by Visit
units on a scaleTocilizumab Plus MTX
Baseline (n=71)6.28 ± 1.06
Week 8 (n=71)3.84 ± 1.29
Change from Baseline to Week 8 (n=71)-2.44 ± 0.98
Week 16 (n=71)3.19 ± 1.23
Change from Baseline to Week 16 (n=71)-3.09 ± 1.01
Week 24 (n=69)2.65 ± 1.23
Change from Baseline to Week 24 (n=69)-3.62 ± 1.22
Statistical analysis
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) and Clinical Remission (CR) as Assessed Using DAS28

DAS28 was calculated using the 28 joints count, the CRP and PtGA of disease activity. The following formula was used to determine DAS28. DAS28 = 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100-mm VAS). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Participants were considered to have low disease activity when DAS28 was less than or equal to (≤) 3.2 and in clinical remission when DAS28 scores were less than (\<) 2.6

Time frame:
Weeks 8, 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) and Clinical Remission (CR) as Assessed Using DAS28
percentage of participantsTocilizumab Plus MTX
Week 8 CR (n=71)14.1
Week 8 LDA (n=71)31.0
Week 16 CR (n=71)39.4
Week 16 LDA (n=71)49.3
Week 24 CR (n=69)47.8
Week 24 LDA (n=69)71.0
SecondarySwollen and Tender Joint Counts

66 and 68 joints were assessed by the physician for tenderness or swelling respectively. The joints were counted as tender/not tender (tender=1; not tender=0) and swollen/not swollen (swollen=1; not swollen=0) and scored. The scores ranged from 0 to 66 for TJC and 0 to 68 for SJC. A negative change from baseline represents an improvement.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Mean · Joints
Swollen and Tender Joint Counts
JointsTocilizumab Plus MTX
Baseline SJC (n=71)19.48 ± 10.97
Week 8 SJC (n=71)6.72 ± 5.76
Change in SJC from Baseline to Week 8 (n=71)-12.76 ± 10.93
Week 16 SJC (n=71)3.73 ± 4.88
Change in SJC from Baseline to Week 16 (n=71)-15.75 ± 9.59
Week 24 SJC (n=69)2.43 ± 4.12
Change in SJC from Baseline to Week 24 (n=69)-16.83 ± 9.51
Baseline TJC (n=71)24.62 ± 11.84
Week 8 TJC (n=71)10.59 ± 8.38
Change in TJC from Baseline to Week 8 (n=71)-14.03 ± 12.21
Week 16 TJC (n=71)7.12 ± 7.25
Change in TJC from Baseline to Week 16 (n=71)-17.49 ± 11.02
Week 24 TJC (n=69)5.03 ± 5.97
Change in TJC from Baseline to Week 24 (n=69)-19.48 ± 10.27
Statistical analysis
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
SecondaryPhysician's Global Assessment of Disease Activity

Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Mean · mm
Physician's Global Assessment of Disease Activity
mmTocilizumab Plus MTX
Baseline (n=71)67.44 ± 17.72
Week 8 (n=71)35.99 ± 20.53
Change from Baseline to Week 8 (n=71)-31.45 ± 17.76
Week 16 (n=71)26.48 ± 20.48
Change from Baseline to Week 16 (n=71)-40.97 ± 20.7
Week 24 (n=69)19.28 ± 17.48
Change from Baseline to Week 24 (n=69)-48.09 ± 19.69
Statistical analysis
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
SecondaryParticipant's Global Assessment of Disease Activity

Participant's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Mean · mm
Participant's Global Assessment of Disease Activity
mmTocilizumab Plus MTX
Baseline (n=71)70 ± 16.84
Week 8 (n=71)42.87 ± 20.67
Change from Baseline to Week 8 (n=71)-27.13 ± 21.60
Week 16 (n=71)33.20 ± 21.16
Change from Baseline to Week 16 (n=71)-36.80 ± 22.43
Week 24 (n=69)24.56 ± 20.15
Change from Baseline to Week 24 (n=69)-45.30 ± 22.74
Statistical analysis
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
SecondaryParticipant's Global Assessment of Pain

Participant's global assessment of pain was performed using a 100 mm VAS ranging from no pain (0) at the left edge to unbearable pain (100) at the right edge. The distance in mm from the left edge of the scale was measured. A negative change from baseline represents an improvement.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Mean · mm
Participant's Global Assessment of Pain
mmTocilizumab Plus MTX
Baseline (n=71)69.73 ± 17.60
Week 8 (n=71)42.34 ± 19.25
Change from Baseline to Week 8 (n=71)-27.39 ± 19.44
Week 16 (n=71)33.94 ± 21.05
Change from Baseline to Week 16 (n=71)-35.79 ± 21.52
Week 24 (n=69)25.54 ± 21.37
Change from Baseline to Week 24 (n=69)-44.04 ± 25.11
Statistical analysis
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
SecondaryCRP Levels

CRP is a marker of acute phase inflammation and is measured in mg/L. A negative change from baseline represents an improvement.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Mean · mg/L
CRP Levels
mg/LTocilizumab Plus MTX
Baseline (n=62)11.98 ± 15.04
Week 8 (n=65)5.11 ± 14.12
Change from Baseline to Week 8 (n=61)-6.68 ± 17.88
Week 16 (n=67)3.84 ± 11.91
Change from Baseline to Week 16 (n=60)-8.0 ± 18.39
Week 24 (n=68)5.53 ± 14.07
Change from Baseline to Week 24 (n=60)-5.97 ± 21.12
Statistical analysis
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
SecondaryErythrocyte Sedimentation Rate (ESR)

ESR is a marker of inflammation and is measured in millimeters per hour (mm/hour). A negative change from baseline represents an improvement.

Time frame:
Baseline, Weeks 8, 16 and 24
Reported as:
Mean · mm/hour
Erythrocyte Sedimentation Rate (ESR)
mm/hourTocilizumab Plus MTX
Baseline (n=71)36.13 ± 24.82
Week 8 (n=71)9.04 ± 8.83
Change from Baseline to Week 8 (n=71-27.09 ± 22.98
Week 16 (n=71)8.71 ± 6.39
Change from Baseline to Week 16 (n=71)-27.42 ± 23.07
Week 24 (n=69)10.3 ± 12.81
Change from Baseline to Week 24 (n=69)-25.72 ± 27.54
Statistical analysis
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
  • Tocilizumab Plus MTX · Wilcoxon signed rank test · p = <0.0005
PrimaryPercentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)

AEs, SAEs and AESI were recorded from the Screening Visit until the final visit at Week 24.

Time frame:
Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)
percentage of participantsTocilizumab Plus MTX
AEs14.1
SAE2.8
AESI4.2

Adverse events

Collected over Adverse events were recorded from the date of screening until the final visit at Week 24. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab Plus MTX—2/71 (2.8%)7/71 (9.9%)
Most frequent serious events
Most frequent serious events
EventTocilizumab Plus MTX
Neoplasm - SkinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/71
Exacerbation of RAImmune system disorders1/71
Most frequent other events
Most frequent other events
EventTocilizumab Plus MTX
LeukocytopeniaBlood and lymphatic system disorders3/71
Elevated ASTHepatobiliary disorders2/71
ThrombocytopeniaBlood and lymphatic system disorders2/71

Baseline characteristics

Intent-to-Treat (ITT) Population: all participants enrolled in the study who completed the baseline visit and received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Tocilizumab Plus MTX
Mean49.76 ± 12.37
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab Plus MTX
Female61
Male10
08

Study locations

3 sites
  • Banja Luka, 78 000, Bosnia and Herzegovina
  • Sarajevo, 71000, Bosnia and Herzegovina
  • Tuzla, 75000, Bosnia and Herzegovina
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2010
First posted
Nov 5, 2010
Start
Feb 2011
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Oct 20, 2014
Last update
Nov 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01235507
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 5, 2010
Start date
Feb 2011
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Oct 20, 2014
Last update
Nov 7, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Tocilizumab

Start the discussion